Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for Hepatitis Delta Virus (HDV) Infection
BEIJING, China & GOTHENBURG, Sweden — 2025-10-24 — Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection. The EMA’s ODD is assigned to investigational therapies of life-threatening or […]
Ribo showcases new clinical data from its leading siRNA programs at ESC 2025, underscoring significant progress and achievements in advancing cardiovascular therapies
SuZhou Ribo life science Ltd. Co. and Ribocure Pharmaceuticals AB (Ribo) presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline. Ribo presented results from its ApoC3-silencing RBD5044 program`s Phase 1 clinical trial, which included single and multiple ascending dose studies (n=72 healthy […]
Distinguished Swedish Investors Back Leading Biotech Company in GoCo Health Innovation City to Advance siRNA Therapies
Mölndal, July 2nd 2025 — We are delighted to announce that distinguished Swedish investors Erik Selin and Jacob Torell have joined Ribocure as new shareholders. Through a direct investment totaling USD 33 million, Erik Selin now holds 32.65% of Ribocure shares, while Jacob Torell holds 1%. We thereby warmly welcome Erik Selin as a new […]
Ribocure Pharmaceuticals represented at European Liver Congress, EASL, in Vienna
Li-ming Gan, CEO at Ribocure Pharmaceuticals, is for the first time showing our preclinical PoC data at the EASL meeting this week. The study was conducted using our mouse surrogate molecule in an in-house developed mouse model of NASH with elevated hepatic HSD expression. HSD17B13 is a genetically identified target strongly associated with liver steatosis […]
Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial.
Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial to evaluate efficacy and safety of its novel siRNA asset for treatment of chronic hepatitis B infection. Ribocure Pharmaceuticals AB, a pioneering Swedish biotech company and the international research center of Ribo Life Science Ltd, focused on development of cutting-edge RNA therapeutics, is delighted to […]
Both building and Ribocure team grow!
In June we move into the entire fifth floor of the GoCo Clinic building and established a unique “from bench-to-bed” set-up with an R&D department, a Ph2 clinical trial unit (Ribocure Clinic) and an in vitro human cell lab.
GoCo House Lunch Launch
GoCo House Lunch Launch took place and we were there from Ribocure Pharmaceuticals to meet our future neighbours and potential collaborators. The excitement is high to expand our business and for the transition in to our new facilities in GoCo Clinic in June!
World’s first siRNA-based FXI silencing agent
World’s first siRNA-based FXI silencing agent enters clinical development – an important step toward a new generation of anti-thrombotic therapies for our patients! Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.On February 6th, 2023, Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to […]
Ribocure participated in The Innovative Ecosystem at GoCo Arena event
Ribocure participated in The Innovative Ecosystem at GoCo Arena event and pitched our vision and aims in just 3 minutes. The purpose was to create new conditions for future collaborations with a workshop format and speed dating.
Visit at GoCo and Gothenburg by one of the founders
Visit at GoCo and Gothenburg by one of the founders, Dr Hongyan Zhang, from the parent comany. Impressed and inspired by the vibrant GoCo environment, Swedish efficiency and quality in construction and design. Full endorsement for our establishment and further expansion at GoCo Clinic!
